Therefore, pharmacological inhibition of PD1-PDL1 inhibition has emerged as one of the most promising therapeutic strategies to strengthen the immune response against a broad-spectrum of PDL1-expressing cancers [7]. This evidence concerns the gene CD274 and cancer.